Results 221 to 230 of about 401,656 (304)

DMS‐MaPseq and DREEM Analyses Implicate the Critical Role of RNA Structural Dynamics in Turnip Yellow Mosaic Virus Pathogenicity

open access: yesAdvanced Science, EarlyView.
RNA structural profiling of Turnip Yellow Mosaic Virus by DMS‐MaPseq and DREEM analyses uncover that viral genome‐wide RSS is highly complicated and heterogeneous, with alternative RSSs widely distributed across the genome. Notably, the viral 3’ tRNA‐like structure adopts alternative conformations in vivo.
Jiaying Zhu   +7 more
wiley   +1 more source

PIEZO1 is Required for Acute Myeloid Leukemia Progression and Leukemia Stem Cell Maintenance via HIF1A‐SLC7A11 Axis‐Mediated Ferroptosis Defense

open access: yesAdvanced Science, EarlyView.
This study identifies the mechanosensor PIEZO1 as a key factor in promoting acute myeloid leukemia progression and uncovers a ferroptosis defense system mediated by PIEZO1‐HIF1A‐SLC7A11 axis that is essential for leukemia stem cell maintenance. This ferroptotic defense system may represent a unique vulnerability for leukemia stem cells, providing a ...
Tiantian Zhang   +10 more
wiley   +1 more source

Mechanism‐Informed Machine Learning Enables Discovery of Oncolytic Peptides for Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
MISPOP integrates ensemble learning with membrane‐active physicochemical priors to identify Dermaseptin‐S9, a natural oncolytic peptide that disrupts tumor membranes, triggers immunogenic cell death, and shows strong antitumor activity. The study illustrates a mechanism‐informed route from peptide sequence data to cancer immunotherapy leads.
Wen Zhang   +11 more
wiley   +1 more source

First report of therapeutic investigation and metabolic profiling of edible mushroom Agaricus flocculosipes. [PDF]

open access: yesAMB Express
Sreekala D   +6 more
europepmc   +1 more source

Ciclopirox Olamine Inhibits the NLRP3 Inflammasome to Alleviate Inflammatory Diseases

open access: yesAdvanced Science, EarlyView.
There is no drug targeting the NLRP3 inflammasome that has been approved for use in clinical settings. Ciclopirox olamine (CPX), an antifungal agent approved by the US Food and Drug Administration (FDA), is identified as a specific and potent NLRP3 inflammasome inhibitor. CPX targets the NACHT domain of NLRP3 at Y381 to impair NLRP3 oligomerization and
Xinyu Xia   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy